Trials / Completed
CompletedNCT02362048
ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer
A Phase 2 Proof-of-Concept Study of ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 77 (actual)
- Sponsor
- Acerta Pharma BV · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
ACP-196 Alone and in Combination with Pembrolizumab in Subjects with Advanced or Metastatic Pancreatic Cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ACP-196 | |
| DRUG | ACP-196 in combination with pembrolizumab |
Timeline
- Start date
- 2015-05-01
- Primary completion
- 2017-03-01
- Completion
- 2017-03-01
- First posted
- 2015-02-12
- Last updated
- 2019-10-01
- Results posted
- 2019-10-01
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02362048. Inclusion in this directory is not an endorsement.